financetom
Business
financetom
/
Business
/
National CineMedia Q4 Earnings Rise, Revenue Falls; Q1 Revenue Outlook Issued
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
National CineMedia Q4 Earnings Rise, Revenue Falls; Q1 Revenue Outlook Issued
Mar 6, 2025 2:16 PM

04:57 PM EST, 03/06/2025 (MT Newswires) -- National CineMedia ( NCMI ) reported Q4 earnings late Thursday of $0.26 per diluted share, up from $0.24 a year earlier.

Three analysts polled by FactSet expected $0.18.

Revenue for the quarter ended Dec. 26 was $86.3 million, down from $90.9 million a year earlier.

Four analysts surveyed by FactSet expected $84.5 million.

The company expects Q1 revenue of $34 million to $36 million. Four analysts polled by FactSet expect $41.8 million.

Shares of the company fell 8.7% in recent after-hours activity.

Price: 5.80, Change: -0.55, Percent Change: -8.66

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dynamite Blockchain to Buy Kaspa Mining Limited For About C$4.8 Million
Dynamite Blockchain to Buy Kaspa Mining Limited For About C$4.8 Million
Dec 3, 2024
07:49 AM EST, 12/03/2024 (MT Newswires) -- Dynamite Blockchain (BLOX.CN) on Tuesday entered into a binding arm's length securities exchange agreement as it moved to buy all outstanding shares of Kaspa Mining Limited for a total consideration of about C$4.8 million. The total consideration for the acquisition will be 30 million common shares of the company, at a deemed issue...
Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million
Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million
Dec 3, 2024
07:47 AM EST, 12/03/2024 (MT Newswires) -- Coherus BioSciences ( CHRS ) said Tuesday that it has agreed to divest its biosimilar drug Udenyca, which is based on Amgen's ( AMGN ) Neulasta, to Intas Pharmaceuticals for up to $558.4 million. The company said the transaction includes an upfront payment of $483.4 million, as well as $75 million in potential...
Core & Main's Fiscal Q3 Earnings, Net Sales Rise; Fiscal 2024 Sales Guidance Lifted
Core & Main's Fiscal Q3 Earnings, Net Sales Rise; Fiscal 2024 Sales Guidance Lifted
Dec 3, 2024
07:45 AM EST, 12/03/2024 (MT Newswires) -- Core & Main ( CNM ) reported fiscal Q3 earnings Tuesday of $0.69 per share, up from $0.65 a year earlier. Four analysts polled by FactSet expected $0.64. Net sales for the quarter ended Oct. 27 were $2.04 billion, up from $1.83 billion a year earlier. Analysts surveyed by FactSet expected $1.99 billion....
Top Premarket Decliners
Top Premarket Decliners
Dec 3, 2024
07:46 AM EST, 12/03/2024 (MT Newswires) -- TruBridge ( TBRG ) shares were down 22% pre-bell Tuesday following a muted session. KalVista Pharmaceuticals ( KALV ) stock was 22% lower after a 2.1% gain on Monday. Gelteq Ltd. ( GELS ) shares were down 21%, paring Monday's rally. Centuri Holdings ( CTRI ) stock was 21% lower after a 2.3%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved